Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Exclusion Criteria

• •Previous treatment for prostate cancer
• •Previous trans-urethral resection of the prostate
• •Patients who are lymph node positive or have other metastatic disease
• •Use of urethral catheter
• •Current treatment with a 5-alpha reductase inhibitor or α-adrenoceptor antagonist.
• •History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
• •Hypersensitivity towards any component of the investigational product
• •Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.
• •Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)
• •Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.